BBOT (BridgeBio Oncology Therapeutics) Other Current Receivables: $0.15 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.42
View Full Analysis

What is BridgeBio Oncology Therapeutics Other Current Receivables?

BridgeBio Oncology Therapeutics BBOT -4.76% 12 Other Current Receivables is $0.15 Mil as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

BridgeBio Oncology Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.15 Mil.

BridgeBio Oncology Therapeutics's quarterly Other Current Receivables increased from Sep. 2025 ($0.23 Mil) to Dec. 2025 ($0.39 Mil) but then stayed the same from Dec. 2025 ($0.39 Mil) to Mar. 2026 ($0.15 Mil).

BridgeBio Oncology Therapeutics's annual Other Current Receivables declined from Dec. 2023 ($1.72 Mil) to Dec. 2024 ($0.08 Mil) but then increased from Dec. 2024 ($0.08 Mil) to Dec. 2025 ($0.39 Mil).

BridgeBio Oncology Therapeutics Other Current Receivables Related Terms

BridgeBio Oncology Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Other Current Receivables Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Other Current Receivables
1.72 0.08 0.39

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 1.08 0.23 0.39 0.15
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.15 Mil mean?
BridgeBio Oncology Therapeutics (BBOT) has a Other Current Receivables of $0.15 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' Other Current Receivables too high?
BridgeBio Oncology Therapeutics' current Other Current Receivables is $0.15 Mil. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Other Current Receivables compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' Other Current Receivables of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Other Current Receivables is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Other Current Receivables of $0.15 Mil. The current Other Current Receivables is $0.15 Mil. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Other Current Receivables is $0.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.42
Price